128 related articles for article (PubMed ID: 22690525)
21. Immunohistochemical analysis of cyclin D1 and p53 in multiple myeloma: relationship to proliferative activity and prognostic significance.
Markovic O; Marisavljevic D; Cemerikic V; Suvajdzic N; Milic N; Colovic M
Med Oncol; 2004; 21(1):73-80. PubMed ID: 15034217
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia.
Lai R; O'Brien S; Maushouri T; Rogers A; Kantarjian H; Keating M; Albitar M
Cancer; 2002 Sep; 95(5):1071-5. PubMed ID: 12209693
[TBL] [Abstract][Full Text] [Related]
23. [Clinical usefulness of serum beta2-microglobulin determination in patients with multiple myeloma].
Kraj M; Maj S; Pogłód R; Rostkowska J
Acta Haematol Pol; 1989; 20(2):140-51. PubMed ID: 2700533
[TBL] [Abstract][Full Text] [Related]
24. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
[TBL] [Abstract][Full Text] [Related]
25. Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
Nakashima J; Tachibana M; Horiguchi Y; Oya M; Ohigashi T; Asakura H; Murai M
Clin Cancer Res; 2000 Jul; 6(7):2702-6. PubMed ID: 10914713
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors in multiple myeloma.
Kyle RA
Stem Cells; 1995 Aug; 13 Suppl 2():56-63. PubMed ID: 8520513
[TBL] [Abstract][Full Text] [Related]
27. [The analysis of prognostic variables in 123 patients with multiple myeloma].
Xu Y; Deng SH; Mai YJ; Li X; Qi PJ; Zhao YZ; Zou DH; Wang YF; Qian LS; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):330-4. PubMed ID: 17877163
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of correction of serum beta 2-microglobulin levels for serum creatinine in multiple myeloma.
Scudla V; Vavrdová V; Budíková M; Indrák K
Acta Univ Palacki Olomuc Fac Med; 1991; 131():257-64. PubMed ID: 1840347
[TBL] [Abstract][Full Text] [Related]
29. [Expression and clinical significance of beta-catenin in multiple myeloma].
Li J; Zhang DB; Luo SK; Zhao Y; Huang BH; Gu JL
Ai Zheng; 2007 Sep; 26(9):1010-4. PubMed ID: 17927863
[TBL] [Abstract][Full Text] [Related]
30. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
[TBL] [Abstract][Full Text] [Related]
31. Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Stella-Holowiecka B; Czerw T; Holowiecka-Goral A; Giebel S; Wojnar J; Holowiecki J
Transplant Proc; 2007 Nov; 39(9):2893-7. PubMed ID: 18022010
[TBL] [Abstract][Full Text] [Related]
32. [Prognostic value of some biochemical and immunologic factors in the management of multiple myeloma].
Abdulkadyrov KM; Stel'mashenko LV; Bessmel'tsev SS; Lubo-Lesnichenko IF; Sel'tser AV; Rozanova OE; Gubarenko NK; Bubnova LN; Mnuskina MM; Zhuchikhina AA; Blinov MN; Gritskevich NL
Vopr Onkol; 1998; 44(3):304-9. PubMed ID: 9695777
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival.
Vande Broek I; Leleu X; Schots R; Facon T; Vanderkerken K; Van Camp B; Van Riet I
Haematologica; 2006 Feb; 91(2):200-6. PubMed ID: 16461304
[TBL] [Abstract][Full Text] [Related]
34. [Serum interleukin-6 in multiple myeloma: I. Relation to selected laboratory indicators of disease].
Scudla V; Bacovský J; Budíková M; Klímová D; Faltýnek L
Vnitr Lek; 1995 Sep; 41(9):593-8. PubMed ID: 7483349
[TBL] [Abstract][Full Text] [Related]
35. Correlation of plasma cell percentages by CD138 immunohistochemistry, cyclin D1 status, and CD56 expression with clinical parameters and overall survival in plasma cell myeloma.
Dunphy CH; Nies MK; Gabriel DA
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):248-54. PubMed ID: 17721267
[TBL] [Abstract][Full Text] [Related]
36. [The significance of lactate dehydrogenase and beta 2-microglobulin levels for the assessment of the prognosis and choice of therapy in multiple myeloma].
Iakovleva SV; Andreeva NE; Izgorodin AS
Ter Arkh; 1995; 67(7):35-9. PubMed ID: 7482303
[TBL] [Abstract][Full Text] [Related]
37. CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients.
Domingo-Domènech E; Domingo-Clarós A; Gonzàlez-Barca E; Beneitez D; Alonso E; Romagosa V; De Sanjos S; Petit J; Grañena A; Fernández de Sevilla A
Haematologica; 2002 Oct; 87(10):1021-7. PubMed ID: 12368155
[TBL] [Abstract][Full Text] [Related]
38. Syndecan-1 in multiple myeloma: relationship to conventional prognostic factors.
Aref S; Goda T; El-Sherbiny M
Hematology; 2003 Aug; 8(4):221-8. PubMed ID: 12911939
[TBL] [Abstract][Full Text] [Related]
39. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.
Andersen NF; Standal T; Nielsen JL; Heickendorff L; Borset M; Sørensen FB; Abildgaard N
Br J Haematol; 2005 Jan; 128(2):210-7. PubMed ID: 15638855
[TBL] [Abstract][Full Text] [Related]
40. Effect of complete response on outcome following autologous stem cell transplantation for myeloma.
Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Witzig TE; Lust JA; Larson D; Therneau TM; Kyle RA; Litzow MR; Greipp PR; Gertz MA
Bone Marrow Transplant; 2000 Nov; 26(9):979-83. PubMed ID: 11100277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
